C Salliot

Summary

Publications

  1. ncbi Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
    C Salliot
    Paris Descartes University, Medicine Faculty, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 68:1100-4. 2009
  2. ncbi Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
    C Salliot
    Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 68:25-32. 2009
  3. ncbi Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases
    E Régnier-Rosencher
    Department of Dermatology, Hopital Cochin, APHP, Universite Rene Descartes Paris V, Paris, France
    Dermatology 224:72-83. 2012
  4. ncbi Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
    A Ruyssen Witrand
    Paris Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 25:430-6. 2007

Collaborators

Detail Information

Publications4

  1. ncbi Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
    C Salliot
    Paris Descartes University, Medicine Faculty, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 68:1100-4. 2009
    ..To perform a systematic literature review of the long-term safety of methotrexate (MTX) monotherapy in rheumatoid arthritis (RA)...
  2. ncbi Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
    C Salliot
    Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 68:25-32. 2009
    ..Recently, new biological agents have become available. Their safety is an important issue...
  3. ncbi Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases
    E Régnier-Rosencher
    Department of Dermatology, Hopital Cochin, APHP, Universite Rene Descartes Paris V, Paris, France
    Dermatology 224:72-83. 2012
    ..The incidence of severe infections is increased under biologic therapies and the skin is the second localization...
  4. ncbi Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
    A Ruyssen Witrand
    Paris Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 25:430-6. 2007
    ..The aim of this study was to assess the complication rate after surgery in such patients, to assess the effect of interrupting TNF blocker therapy, and to identify other potential predictors of complications...